Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...

The presence of type 2 inflammation in asthma or CRSwNP can be detected by blood eosinophil count, which measures the level of a type of white blood cell. GSK is redefining the future of respiratory ...

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups.

The Nose Knows: Nasal Swab Detects Asthma Type in Kids Jan. 2, 2025 — A new, non-invasive nasal swab test for kids that diagnoses specific asthma subtype, or endotype, could help clinicians ...

With Dr. Camp’s expertise, my personal experiences, and customer feedback in mind, I’ve produced the below guide to the five best brushes for stimulating hair growth. I’d be remiss if I ...

GSK plc has announced that new drug applications have been accepted ... In China, the submitted indications are for an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...